To further explore the potential therapeutic effects of PPAR-γ in non-segmental vitiligo, we investigated the potential effects of rosiglitazone, a specific agonist of PPAR-γ, on melanin synthesis according to the results of Gene-drug prediction. Here, PPARG is linked to vitiligo.